Idenix Pharmaceuticals
Profile Unclaimed

Idenix Pharmaceuticals Reviews

5 Reviews
5 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
Idenix Pharmaceuticals CEO Ronald C. Renaud Jr.
Ronald C. Renaud Jr.
0 Ratings

    A bumpy ride at times, but overall a great experience

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Current Employee - Anonymous Employee in Cambridge, MA
    Current Employee - Anonymous Employee in Cambridge, MA

    I have been working at Idenix Pharmaceuticals full-time (more than 5 years)


    Great opportunities for advancement and broadening of skills/experience


    Obtaining the proper resources (in terms of headcount) sometimes can be challenging

    Advice to ManagementAdvice

    Recently acquired by Merck, the future is uncertain.

    Negative Outlook

Idenix Pharmaceuticals Interviews

Interview Experience

Interview Experience


Getting an Interview

Getting an Interview


Interview Difficulty


Interview Difficulty




    Accounting Interview

    Anonymous Employee
    Anonymous Employee
    Application Details

    I applied online. The process took 5 daysinterviewed at Idenix Pharmaceuticals in February 2008.

    Interview Details

    I received a call from a human resources resume who had seen my resume that I had submitted for a job posted on their website. I went in for interviews with the CFO, VP of Finance and Controller. They made me take a test on using Microsoft Excel worksheets, to see if I really knew how to use it.

    Interview Questions
    No Offer
    Positive Experience
    Average Interview

Idenix Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters Cambridge, MA
Size 50 to 149 Employees
Founded 2003
Type Company - Public (IDIX)
Industry Biotech & Pharmaceuticals
Revenue $10 to $25 million (USD) per year

Idenix Pharmaceuticals is not suffering from an identity crisis -- it is clear in its focus on identifying treatments for viral diseases. The firm develops orally administered drugs to combat chronic hepatitis C (HCV). It has one marketed drug for hepatitis B (HBV), Telbivudine, sold under the brand names Tyzeka in the US and Sebivo internationally. It markets the product with Novartis, which also owns about 40% of Idenix. As part of the arrangement, Idenix receives royalties from Novartis for telbivudine sales. Idenix's other candidates are in various stages of clinical... More

Work at Idenix Pharmaceuticals? Share Your Experiences

Idenix Pharmaceuticals

Click to Rate